KR100595919B1 - 디페닐에틸렌 화합물의 신규한 헤테로고리 유사체 - Google Patents

디페닐에틸렌 화합물의 신규한 헤테로고리 유사체 Download PDF

Info

Publication number
KR100595919B1
KR100595919B1 KR1020007000173A KR20007000173A KR100595919B1 KR 100595919 B1 KR100595919 B1 KR 100595919B1 KR 1020007000173 A KR1020007000173 A KR 1020007000173A KR 20007000173 A KR20007000173 A KR 20007000173A KR 100595919 B1 KR100595919 B1 KR 100595919B1
Authority
KR
South Korea
Prior art keywords
linear
independently
compound
delete delete
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007000173A
Other languages
English (en)
Korean (ko)
Other versions
KR20010021615A (ko
Inventor
네오기파르타
나그비쉬와지트
메디첼라사리야나라이아나
데이데벤드라나쓰
Original Assignee
테라코스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/074,925 external-priority patent/US6245814B1/en
Application filed by 테라코스, 인코포레이티드 filed Critical 테라코스, 인코포레이티드
Publication of KR20010021615A publication Critical patent/KR20010021615A/ko
Application granted granted Critical
Publication of KR100595919B1 publication Critical patent/KR100595919B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020007000173A 1998-05-08 1999-05-07 디페닐에틸렌 화합물의 신규한 헤테로고리 유사체 Expired - Fee Related KR100595919B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/074,925 US6245814B1 (en) 1998-05-08 1998-05-08 Diphenylethylene compounds
US09/074,925 1998-05-08
US9/074,925 1998-05-08
US09/287,237 US6331633B1 (en) 1998-05-08 1999-04-06 Heterocyclic analogs of diphenylethylene compounds
US09/287,237 1999-04-06
US9/287,237 1999-04-06
PCT/US1999/009982 WO1999058127A1 (en) 1998-05-08 1999-05-07 Novel heterocyclic analogs of diphenylethylene compounds

Publications (2)

Publication Number Publication Date
KR20010021615A KR20010021615A (ko) 2001-03-15
KR100595919B1 true KR100595919B1 (ko) 2006-07-03

Family

ID=26756222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007000173A Expired - Fee Related KR100595919B1 (ko) 1998-05-08 1999-05-07 디페닐에틸렌 화합물의 신규한 헤테로고리 유사체

Country Status (13)

Country Link
US (1) US6331633B1 (enExample)
EP (1) EP1007039B1 (enExample)
JP (1) JP4577985B2 (enExample)
KR (1) KR100595919B1 (enExample)
CN (1) CN1151139C (enExample)
AT (1) ATE260906T1 (enExample)
AU (1) AU751235C (enExample)
CA (1) CA2295599C (enExample)
DE (1) DE69915223T2 (enExample)
DK (1) DK1007039T3 (enExample)
ES (1) ES2216513T3 (enExample)
PT (1) PT1007039E (enExample)
WO (1) WO1999058127A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041941B2 (en) 1997-04-07 2006-05-09 Patented Medical Solutions, Llc Medical item thermal treatment systems and method of monitoring medical items for compliance with prescribed requirements
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
DE60022207T2 (de) 1999-08-31 2006-06-22 Incyte San Diego Incorporated, San Diego Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
ES2275654T5 (es) 2000-01-21 2012-06-07 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
WO2003009807A2 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
KR100468429B1 (ko) * 2001-09-07 2005-01-27 주식회사 엔바이오테크놀러지 알파-글루코시다제 저해활성이 있는 소나무 추출물 및 그추출방법
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2003282920A1 (en) 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
JP2007530417A (ja) 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20080267888A1 (en) * 2005-05-26 2008-10-30 Pandey Surendrakumar Satyanara Heterocyclic Derivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007042878A1 (en) * 2005-10-07 2007-04-19 Orchid Research Laboratories Limited Novel heterocyclic analogs of biphenyl ethers
KR101016875B1 (ko) * 2006-06-23 2011-02-22 현대중공업 주식회사 밀폐형 방청유 도포장치
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
WO2022045836A1 (ko) * 2020-08-28 2022-03-03 (주)셀로스바이오텍 신규 티오히단토인 유도체 및 이의 용도

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683009A (en) 1968-10-10 1972-08-08 Du Pont {60 , {62 -bis(trifluoromethyl) stilbenes
US3609183A (en) 1969-01-08 1971-09-28 Parke Davis & Co {60 -{8 {11 -(dimethylaminoalkyl)phenyl{9 -4-methoxy-{60 {40 -nitrostilbene compounds
US4312855A (en) 1970-11-16 1982-01-26 Colgate-Palmolive Company Compositions containing aminopolyureylene resin
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US4284637A (en) 1978-03-09 1981-08-18 Mitsubishi Chemical Ind., Limited Pharmaceutically active 2-(4-aminobutoxy)stilbenes
JPS6045632B2 (ja) 1978-03-09 1985-10-11 三菱化学株式会社 ω−アミノアルコキシスチルベン類及びその酸付加塩
DE2832213A1 (de) 1978-07-21 1980-01-31 Bayer Ag Stilbenderivate, verfahren zu ihrer herstellung und ihre verwendung als insektizide
JPS5629548A (en) 1979-08-16 1981-03-24 Mitsubishi Chem Ind Ltd Omega-aminoalkoxystilbenes and their acid addition salts
FR2562539B1 (fr) 1984-04-06 1987-04-17 Chauvin Blache Lab Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
US4716905A (en) 1985-09-25 1988-01-05 Fluorochrome, Inc. Method of retrograde fluorescent labeling of neurons
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
GB8716650D0 (en) 1987-07-15 1987-08-19 Ici Plc Use of olefinic compounds
CA1340955C (en) 1988-02-24 2000-04-11 Michael Klaus Stilbene derivatives
US5250562A (en) 1988-02-24 1993-10-05 Hoffmann-La Roche Inc. Stilbene derivatives
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
DE3926148A1 (de) 1989-08-08 1991-02-28 Basf Ag Diarylacetylene, ihre herstellung und verwendung
US5189056A (en) 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
US5162337A (en) 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
DK0498095T3 (da) 1991-02-05 1995-06-19 Merrell Dow Pharma Sulfoniske stilbenderivater til behandling af virussygdomme
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
US5171753A (en) 1991-05-15 1992-12-15 A. H. Robins Company, Incorporated Derivatives of 2-amino-1-phenylethanol having antiulcer activity
ATE272068T1 (de) 1991-11-07 2004-08-15 Nanotronics Inc Hybridisierung von mit chromophoren und fluorophoren konjugierten polynukleotiden zur erzeugung eines donor-donor energietransfersystems
US5246936A (en) 1991-12-20 1993-09-21 American Cyanamid Company Methods and compositions containing pesticides and stilbene compounds for enhanced pesticidal activity
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5314693A (en) 1992-02-07 1994-05-24 Kioritz Corporation Pest control chemicals against pine wood nematodes
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
CA2135488A1 (en) 1993-03-10 1994-09-15 Koichi Hashimoto Stilbene derivative and stilbene analog derivative, and use thereof
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
IT1264988B1 (it) 1993-12-14 1996-10-17 Sigma Prod Chim Composizioni cosmetiche e dermatologiche per la protezione da radiazioni uv contenenti derivati dallo stilbene
TW308598B (enExample) 1994-01-14 1997-06-21 Hoffmann La Roche
JPH08143566A (ja) * 1994-11-25 1996-06-04 Terumo Corp キナゾリン誘導体及びそれを含有する医薬組成物
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
CA2174582A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulphuric acid esters of amino-sugars
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes

Also Published As

Publication number Publication date
AU3974199A (en) 1999-11-29
US6331633B1 (en) 2001-12-18
CN1151139C (zh) 2004-05-26
WO1999058127A1 (en) 1999-11-18
EP1007039B1 (en) 2004-03-03
PT1007039E (pt) 2004-07-30
DE69915223T2 (de) 2005-01-27
CA2295599A1 (en) 1999-11-18
ES2216513T3 (es) 2004-10-16
CN1273528A (zh) 2000-11-15
ATE260906T1 (de) 2004-03-15
AU751235B2 (en) 2002-08-08
KR20010021615A (ko) 2001-03-15
AU751235C (en) 2004-06-24
CA2295599C (en) 2009-01-20
EP1007039A4 (en) 2002-05-22
DE69915223D1 (de) 2004-04-08
DK1007039T3 (da) 2004-07-12
JP2002514598A (ja) 2002-05-21
EP1007039A1 (en) 2000-06-14
JP4577985B2 (ja) 2010-11-10
HK1028348A1 (en) 2001-02-16

Similar Documents

Publication Publication Date Title
KR100595919B1 (ko) 디페닐에틸렌 화합물의 신규한 헤테로고리 유사체
Burant et al. Troglitazone action is independent of adipose tissue.
KR101934328B1 (ko) 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
TW200918049A (en) Compounds useful as medicaments
KR20080106455A (ko) 대사장애의 조합치료
CZ20032927A3 (cs) Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV
KR20110107287A (ko) 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
US6525093B1 (en) Compounds to treat diabetes and associated conditions
WO2016057658A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
KR101391905B1 (ko) 물질대사 장애의 치료용 화합물
CN1162152C (zh) 糖尿病治疗剂
KR101668443B1 (ko) 아모디아퀸을 유효성분으로 함유하는 대사성 질환의 예방, 개선, 또는 치료용 조성물
WO2006001092A1 (ja) インスリン分泌促進剤
HK1028348B (en) Novel heterocyclic analogs of diphenylethylene compounds
Lohray et al. Indole-containing thiazolidine-2, 4-diones as novel euglycemic and hypolipidemic agents: DRF-2189
WO1996003148A1 (en) Method and drug for treating diabetes
Tripathi et al. Asian Journal of Pharmaceutical Education and Research

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20120611

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130627

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130627